Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its third-quarter 2024 earnings, highlighting a steady increase in revenue and strategic developments in product innovation and market expansion. Despite ...
Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...
More recently, it has become evident that microglia, the resident macrophages of the CNS that drive neuroinflammation, may also be activated in obesity and can be relevant for regulation of ...
Although craniopharyngioma is a benign tumour, it can cause complications due to its growth along the critical nerve structures of the brain close to the hypothalamus and the pituitary gland. Given ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.
Jefferies thinks “way more upside” comes from Rhythm’s second generation hypothalamic obesity drugs with better profiles and intellectual property out to 2040s. These should be de-risked if ...
Use your voice to deepen the dialogue and engage with stories of courage, endurance, community, triumph, and the pursuit of truth in SA. Contact the public editor with feedback for our journalists, ...
We have handpicked some of the best captions for different occasions, moods, and styles that will go well with your photos, Stories, and Reels. So what are you waiting for? Pick any of these Instagram ...
Highly pathogenic avian influenza A(H5N1) viruses are circulating among wild birds and poultry in British Columbia, Canada. 1 These viruses are also recognized to cause illness in humans.